- #4D MOLECULAR THERAPEUTICS IPO PLUS#
- #4D MOLECULAR THERAPEUTICS IPO DOWNLOAD#
- #4D MOLECULAR THERAPEUTICS IPO FREE#
#4D MOLECULAR THERAPEUTICS IPO FREE#
Click to get this free reportĤD Molecular Therapeutics, Inc.
#4D MOLECULAR THERAPEUTICS IPO DOWNLOAD#
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. MediWound's revenues are expected to be $4.35 million, down 25.6% from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This developer of treatments for burns and hard-to-heal wounds is expected to post quarterly loss of $0.11 per share in its upcoming report, which represents a year-over-year change of -10%. The results are expected to be released on May 17. MediWound (MDWD), another stock in the same industry, has yet to report results for the quarter ended March 2022. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
#4D MOLECULAR THERAPEUTICS IPO PLUS#
In terms of the Zacks Industry Rank, Medical - Drugs is currently in the bottom 41% of the 250 plus Zacks industries. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Įmpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? What's Next for 4D Molecular Therapeutics, Inc. Shares have lost about 57.6% since the beginning of the year versus the S&P 500's decline of -17.4%. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.ĤD Molecular Therapeutics, Inc. The company has not been able to beat consensus revenue estimates over the last four quarters. This compares to year-ago revenues of $2 million.
, which belongs to the Zacks Medical - Drugs industry, posted revenues of $1.22 million for the quarter ended March 2022, missing the Zacks Consensus Estimate by 39.05%. Over the last four quarters, the company has surpassed consensus EPS estimates two times.ĤD Molecular Therapeutics, Inc. A quarter ago, it was expected that this company would post a loss of $0.82 per share when it actually produced a loss of $0.85, delivering a surprise of -3.66%. This quarterly report represents an earnings surprise of -12.33%.
These figures are adjusted for non-recurring items. This compares to loss of $0.61 per share a year ago. (FDMT) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.73.
0 kommentar(er)
